Navigation Links
Mayo Clinic: New multiple myeloma treatment guidelines personalize therapy for patients
Date:4/1/2013

ROCHESTER, Minn. -- Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy. The guidelines are published in the current issue of the journal Mayo Clinic Proceedings and represent a consensus opinion of hematologists at Mayo Clinic Cancer Center sites in Minnesota, Florida and Arizona.

"Multiple myeloma is an incurable blood cancer that affects more than 20,000 people in the U.S. each year," says lead author Joseph Mikhael, M.D. a hematologist at Mayo Clinic in Arizona. "Over the past decade we have made great progress in understanding the disease, developing drug therapies and increasing overall survival. However, as a medical community we haven't done as good a job at optimizing therapy based on a patient's individual risk factors."

Dr. Mikhael says the new guidelines will help patients with low-risk disease avoid the harsh side effects of therapy and will reserve more intense therapy for patients with aggressive disease.

Among the guidelines:

  • A strong recommendation to enroll patients in clinical trials as the first option for therapy or supportive care.

  • Separating patients by risk into three groups to make the most of new drug therapy: high risk, intermediate risk and low risk. Previous guidelines included only two groups: high risk and standard risk.

  • Adding factors to assess the risk the multiple myeloma poses to the patient, including use of gene expression profiling to help identify patients with high-risk disease.

  • Greater emphasis on delaying stem cell transplants to take advantage of improved chemotherapy, resulting in better responses.

  • Maintenance therapy using drugs such as lenalidomide and bortezomib that balance benefit with short- and long-term toxicity.


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic: Skin problems, joint disorders top list of reasons people visit doctors
2. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
3. Mayo Clinic: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy
4. Mayo Clinic: Antidepressant eases radiation-related mouth pain in head, neck cancer
5. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
6. Mayo Clinic: Drug duo turns on cancer-fighting gene in kidney, breast cancers
7. Mayo Clinic: Common blood pressure drug linked to severe GI problems
8. Mayo Clinic: Molecule thought cancer foe actually helps thyroid tumors grow
9. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
10. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
11. Mayo Clinic: Obesity epidemic fueling rise in rheumatoid arthritis among women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology: